Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like na?ve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.

Clinical information about Hepatitis C is quickly outdated, so Dr. Poordad has assembled expert authors to provide state-of-the-art clinjcal reviews for hepatologists. This issue is uniquely organized to present articles based on therapeutic regimens for certain types of patients:
?Regimens for the Treatment-Na?ve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy....